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AqueSys Implant
By Rohit Varma, MD, MPH
Many of the devices for microinvasive glau-
coma surgery deliver on the promise of a less 
invasive procedure but, as of yet, without the 
desired efficacy. This is likely due to differ-
ences in the mechanism of action between gold standard 
procedures targeting subconjunctival outflow and the 
canal or suprachoroidal approaches. 
AqueSys, Inc., has reinvented the approach to subcon-
junctival outflow. The company’s technology is designed 
to provide a minimally invasive ab interno procedure 
while safely and significantly lowering the IOP of patients 
with early, moderate, and refractory glaucoma. 
DESIGN
The AqueSys Implant is made of a collagen-derived gela-
tin. Upon implantation, the device is designed to create 
a diffuse outflow of aqueous from the anterior chamber 
into the nondissected tissue of the subconjunctival space. 
A well-known gelatin was chosen because it is extremely 
well tolerated by the human body and is noninflamma-
tory. It is also very soft, and this pliability allows the device 
to conform to the ocular tissue, which should minimize 
many of the problems associated with synthetic materials 
(eg, migration, erosion, corneal endothelial damage). The 
gelatin material is cross-linked during manufacturing, which 
makes it permanent. 
PROCEDURE
The AqueSys Implant (Figure 1) is placed through a small 
(approximately 1.6 mm) clear corneal incision via a pre-
loaded IOL-like inserter. Using an ab interno approach, the 
surgeon advances the inserter across the anterior chamber 
into the quadrant of the eye where implantation is planned. 
Upon placing the inserter’s tip at the desired subconjunc-
tival location, the surgeon delivers the device in a fashion 
similar to placing an IOL in the bag. The AqueSys procedure 
is straightforward and can be performed as a primary proce-
dure or in conjunction with cataract surgery. 
One clear benefit of the AqueSys ab interno to sub-
conjunctival approach is that it bypasses all potential 
aqueous outflow obstructions instead of trying to rein-
vigorate an already failing outflow pathway, as occurs in 
other approaches.1,2 The conjunctiva-sparing ab interno 
approach means that additional AqueSys Implants could 
be placed over the course of the patient’s lifetime, if 
An update on some of the technologies and procedures being investigated  
for microinvasive glaucoma surgery.
devices in 
development
Figure 1.  The 6-mm AqueSys Implant is positioned next to an Ahmed Glaucoma Valve (New World Medical, Inc.) (A). Anterior 
segment optical coherence tomography shows the soft AqueSys Implant conforming to the tissue in a human eye (B).
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Figure 2.  Mean IOP, mean percentage reduction from best medicated IOP, and mean number of IOP-lowering medications 
over time in a multicenter clinical study. Patients’ IOP-lowering medications were not washed out prior to surgery. 
CyPass Micro-Stent
By William J. Flynn, MD
Designed for microinvasive glaucoma surgery, 
the CyPass Micro-Stent (Transcend Medical) has 
achieved promising early results in clinical trials. 
The device is implanted in the supraciliary space 
to establish a permanent conduit for aqueous filtration via 
uveoscleral outflow. The uveoscleral outflow pathway is an 
ideal target for therapeutic intervention for a number of rea-
sons. Experimental evidence indicates that there is a nega-
tive pressure gradient between the suprachoroidal space 
and the anterior chamber, which provides a driving force 
for aqueous outflow.1 Clinical experience demonstrates 
that a traumatic or iatrogenic cyclodialysis is associated 
with a significant decrease in IOP, because it creates nontra-
becular outflow through the uveoscleral route.2 Although 
uveoscleral outflow is relatively independent of IOP when 
needed. Furthermore, unlike with more invasive ab externo 
approaches or implants for microinvasive glaucoma surgery 
that require significant retention features (sutures, barbs, 
etc.), the AqueSys device can be removed in a straightfor-
ward procedure with minimal ocular trauma. 
RESULTS
Several multicenter studies are underway in the United 
States, Canada, Europe, Asia, Australia, and South America. 
Figure 2 shows the initial 2-year follow-up results from a 
multicenter study outside the United States in patients 
with mild, moderate, and refractory glaucoma (n = 107). 
The data reflect significant IOP lowering from best medi-
cated preoperative IOPs that was sustained over a 2-year 
period. Follow-up for this study is ongoing.3,4 
AqueSys was granted the CE Mark in Europe in 2011 
for a broad treatment range for patients with mild, mod-
erate, and refractory glaucoma. The company is currently 
enrolling subjects under an approved investigational 
device exemption for its first indication in the United 
States, with an estimated clearance in 2014. 
Rohit Varma, MD, MPH, is a professor with the 
Department of Ophthalmology and Preventive Medicine 
at the University of Southern California, Keck School of 
Medicine, in Los Angeles. He is a paid consultant/advisor 
to AqueSys, Inc. Dr. Varma may be reached at (323) 442-
6411; rvarma@usc.edu. 
1.  Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J. 
2010;4:52-59.
2.  Gedde SJ, Schiffman JC, Feuer WJ, et al; Tube Versus Trabeculectomy Study Group. Treatment outcomes in the 
Tube Versus Trabeculectomy (TVT) Study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789-803.e2.
3.  Gomez IK, Dick B. First results of the innovative minimal-invasive glaucoma surgery technique: AqueSys 
Aquecentesis Procedure. Presented at: XXX Congress of the ESCRS; September 8-12, 2012; Milan, Italy.
4.  Palmberg PF. One year results with the minimally invasive Aquecentesis procedure. Presented at: 6th Interna-
tional Congress on Glaucoma Surgery (ICGS) 2012; September 13-15, 2012; Glasgow, Scotland.
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pressure is at normal levels, a cyclodialysis results in a mark-
edly pressure-dependent increase in uveoscleral outflow.3,4 
Moreover, experience in glaucoma pharmacotherapy dem-
onstrates that some of the most effective IOP-lowering topi-
cal therapies act primarily by increasing uveoscleral outflow.5 
DESIGN
The CyPass (Figure 1) is a fenestrated, miniature stent 
made of biocompatible, nonbiodegradable polyimide 
material that has demonstrated a minimal inflammatory 
or fibrotic reaction in preclinical studies in a rabbit model.6 
The device is 6.35 mm long and has an external diameter of 
510 µm. The inserter for the stent consists of a handpiece 
and a releasable guidewire. The latter was designed to 
atraumatically follow the anatomical plane of the potential 
space between the ciliary body and the sclera.
PROCEDURE
The procedure is performed ab interno. After obtain-
ing a view of the angle with a goniolens, the surgeon 
identifies the key anatomical landmark, the scleral spur. 
Loaded in the inserter, the CyPass is then advanced via 
a paracentesis or phacoemulsification incision across 
the anterior chamber to a position juxtaposed with the 
planned site of insertion. The goniolens is reintroduced 
to view both the CyPass and the scleral spur. The sur-
geon then implants the device by inserting the guidewire 
of the inserter just posterior to the scleral spur and 
advancing the stent so that nearly its entire length is in 
the supraciliary space (Figure 2). The implantation via the 
blunt, “noncutting” dissection of the guidewire creates a 
controlled cyclodialysis that is maintained by the CyPass. 
RESULTS
Multiple clinical studies in Europe and the United States 
are underway or were recently completed. The reports 
on IOP reduction have been favorable and consistent. 
Ianchulev shared the first clinical results of more than  
81 eyes, which achieved a reduction in IOP from 22.9 
to 16.2 mm Hg at 6 months.7 More recently, Hoeh et al 
reported that combining the implantation of the CyPass 
with phacoemulsification provided a sustained decrease 
in IOP that exceeded 35% through 12 months, with more 
than a 50% reduction in medication.8 The safety data from 
these initial 265 patients are encouraging. There have been 
no incidents of erosion of the device or endophthalmitis. 
Nor are there reports of hypotony maculopathy or cho-
roidal effusion. Suprachoroidal hemorrhages have not 
occurred, and postoperative hyphema have been infre-
quent, small, and brief—typically lasting less than 48 hours. 
Finally, the acute IOP spikes that often accompany sponta-
neous closure of a cyclodialysis cleft have not occurred.7,8
The current FDA study is the COMPASS clinical trial 
(compassclinicaltrial.com). This randomized, controlled 
study is twice the size of any previous microstent trials, with 
a total of 505 patients. Subjects are randomized either to 
undergo implantation of the CyPass combined with phaco-
emulsification or to have phacoemulsification alone. The 
study has a robust design, with diurnal IOP measurements 
at baseline, 1 year, and 2 years, all with medication washouts. 
The investigation will be fully enrolled in the next several 
months, again with follow-up for 2 subsequent years.
Figure 1.  The CyPass Micro-Stent is loaded on the guidewire 
of the inserter and implanted in the supraciliary space. 
Figure 2.  The surgeon views the device through a goniolens 
after implantation. 
Figure 3.  Optical coherence tomography image of a CyPass 
Micro-Stent in the supraciliary space. 
(Courtesy of Ike Ahm
ed, M
D.)
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The Hydrus Microstent
By Robert Marquis MD, PhD
The obstruction of aqueous outflow may 
cause ocular hypertension and glaucoma. 
Traditional ab externo glaucoma surgeries 
carry significant risks, including hypotony, 
choroidal effusion and hemorrhage, and bleb- or shunt-
related infections, sometimes arising years after the pro-
cedure. The clear necessity for safer yet effective surgical 
intervention has spawned the new class of microinvasive 
glaucoma surgery, and the initial results of the Hydrus 
Microstent (Ivantis, Inc.) in studies outside the United 
States have been encouraging.
DESIGN
Comparable in size to an eyelash, the Hydrus is made 
from nitinol, a nickel-titanium alloy. Nitinol medical 
devices have been implanted in various anatomical loca-
tions and have demonstrated an excellent safety and bio-
compatibility profile. Initial studies of the Hydrus show 
similar safety in the eye, as discussed later. Figure 1 shows 
the device’s dimensions and curvature, which takes the 
same arc as Schlemm canal. 
PROCEDURE
The Hydrus is loaded inside a handheld injector. At the 
time of surgery, the ophthalmologist observes the nasal 
iridocorneal angle under direct gonioscopy. The injector’s 
tip is advanced through a temporal corneal wound, then 
engaged through the trabecular meshwork and delivered 
into Schlemm canal by the surgeon’s advancing the roller 
wheel mechanism on the injector with his or her index 
finger (Figure 2). 
The procedure uses topical anesthesia and is currently 
under investigation in the United States in patients with 
primary open-angle glaucoma (grade 3 or 4) who are 
Figure 1.  The Hydrus Microstent is designed to dilate 3 clock 
hours of Schlemm canal. The inlet at the right is positioned 
in the anterior chamber to facilitate aqueous flow across the 
trabecular meshwork and through Schlemm canal into the 
collector channels.
CONCLUSION
Supraciliary stenting with the CyPass Micro-Stent offers 
a number of potential advantages over canal surgeries and 
trabecular stents. Because the suprachoroidal space is con-
tinuous and larger than Schlemm canal, it may have a sig-
nificantly higher absorptive capacity for outflow. Moreover, 
because there is a greater area for stenting in the supracho-
roidal space, large devices can be developed. The CyPass 
has almost three times the internal diameter of a trabecular 
microstent and six times the length, allowing additional fen-
estrations that may further enhance outflow. Furthermore, 
the placement of a suprachoroidal stent at its intended site 
of implantation is straightforward, is easily confirmed at the 
time of surgery, and can be imaged postoperatively with 
ultrasound biomicroscopy and optical coherence tomogra-
phy (Figure 3).9 
The CyPass is minimally invasive, ab interno, conjunctiva-
sparing, nonperforating, blebless glaucoma surgery. The 
device creates a controlled cyclodialysis cleft that lowers 
IOP by filtering aqueous from the anterior chamber to 
the suprachoroidal space. The reported outcomes data so 
far are encouraging in terms of a successful and sustained 
reduction in IOP, and the implant appears to be well toler-
ated by the eye. Moreover, the problems of hypotony and 
bleeding—so common with cyclodialysis clefts—have not 
occurred with the CyPass. In this author’s experience, the 
one-step implantation technique is straightforward and 
easily adopted. Nonetheless, the insertion technique is 
undergoing further refinement for yet simpler implantation, 
without the need for surgical gonioscopy.10
William J. Flynn, MD, is a glaucoma specialist in private 
practice in San Antonio, and he is a clinical professor of oph-
thalmology at The University of Texas Health Science Center 
at San Antonio. He is a clinical investigator for Transcend 
Medical in the COMPASS Clinical Trial. Dr. Flynn may be 
reached at (210) 340-1212; flynn@rreyes.net.
1.  Emi K, Pederson JE, Toris CB. Hydrostatic pressure of the suprachoroidal space. Invest Ophthalmol Vis Sci. 
1989;30(2):233-238. 
2.  Barkan O, Boyle SF, Maisler S. On the surgery of glaucoma: mode of cyclodialysis. Am J Ophthalmol. 1936;19:21.
3.  Bill A. The aqueous humour drainage mechanism in the cynomolgus monkey (Macaca irus) with evidence for 
unconventional routes. Invest Ophthalmol Vis Sci. 1965;4:911-919.
4.  Toris CB, Pederson JE. Effect of intraocular pressure on uveoscleral outflow following cyclodialysis in the monkey 
eye. Invest Ophthalmol Vis Sci. 1985;26:1745-1749.
5.  Toris CB. Pharmacotherapies for glaucoma. Curr Mol Med. 2010;10(9):824-840. 
6.  Nguyen QH, Ahmed IK, Craven ER, et al. Biocompatibility of a polyimide suprachoroidal microstent (CyPass) for intra-
ocular pressure lowering in glaucoma: 6 months rabbit animal model. Invest Ophthalmol Vis Sci. 2012;53:e-abstract 3730.
7.  Ianchulev T. Minimally invasive ab interno suprachoroidal device (CyPass) for IOP control in open-angle 
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undergoing phacoemulsification surgery. In many cases, 
the cataract wound may be reused for implantation of 
the Hydrus, obviating the need for an additional incision. 
Surgical time is brief compared with that of traditional ab 
externo procedures. 
Outside the United States, the Hydrus is being evalu-
ated in several studies, including comparative effectiveness 
research against an alternative microinvasive glaucoma 
surgical approach, in both phakic patients and those 
undergoing a combined glaucoma-cataract procedure. 
RESULTS
Efficacy and Safety
More than 500 Hydrus Microstents have been implant-
ed by over 20 surgeons in 10 countries outside the United 
States during the past 3 years. Samuelson and colleagues 
reported the 6-month results of a six-center trial of  
29 patients who underwent combined phacoemulsifica-
tion and Hydrus implantation.1 The average preoperative 
IOP was 24.6 ±5.3 mm Hg after washout from an average 
of 2.2 topical medications. The 1-, 3-, and 6-month data 
showed significant decreases in IOP, averaging 8.7 mm Hg 
at 6 months (Figure 3). No significant complications were 
observed during surgery or during postoperative follow-up 
visits. Remarkably, 79% of patients remained free of medi-
cation with an IOP of 18 mm Hg or less at 6 months. 
In another report, Samuelson and colleagues discussed 
the 6-month results for an additional 40 patients who 
received the Hydrus as an isolated procedure (not com-
bined with cataract extraction).2 The average preoperative 
IOP was 21.6 ±4.4 mm Hg on an average of 1.7 ±1.4 medi-
cations. The 6-month follow-up data showed a significant 
reduction in IOP to 16.9 ±3.8 mm Hg, and the number of 
medications needed was also reduced significantly to 0.6 
(from 1.7 preoperatively). Minor complications, including 
transient hyphema that resolved in less than a week, were 
reported, but no significant complications arose. 
Although both trials were limited by sample size and time 
of follow-up thus far, the results are encouraging and point 
to the need for additional studies.
Current US Investigational Trial
Presently, a 2-year prospective, randomized, controlled 
trial is underway in the United States to determine the 
safety and efficacy of the Hydrus implanted in conjunction 
with phacoemulsification. The control group undergoes 
cataract surgery alone. This study design is important to 
determine the effectiveness of the microstent, because it 
has been established that cataract surgery alone may lower 
IOP significantly. This trial should eventually enroll more 
than 500 patients at more than 30 sites. 
The primary endpoint will be a reduction in IOP of at 
least 20% after medication washout, with 
results measured at the 2-year postopera-
tive time point. The secondary endpoint 
will be the difference in IOP reduction 
between the Hydrus and control groups. 
Safety outcomes will include vision loss, 
changes found during a slit-lamp exami-
nation, endothelial cell loss, and any other 
complications or adverse events.
CONCLUSION
Although topical medications have 
improved with regard to dosing fre-
quency and side effect profile during 
the past 4 decades, surgical innova-
tions have lagged. Blebless procedures 
are of great interest, but an ab externo 
Figure 2.  The device 30 days after its implantation into 
Schlemm canal. The inlet is at the top right of the image.
Figure 3.  In the Hydrus I Study, the implantation of the device in conjunction 
with cataract surgery significantly reduced IOP.1
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iStent Inject
By E. Randy Craven, MD
With the FDA’s clearance of a trabecular 
microbypass stent, the surgical options for glau-
coma will continue to expand as better technol-
ogy is developed. Based on the 2-year data from 
the first-generation iStent Trabecular Micro-Bypass Stent 
(Glaukos Corporation), significantly more eyes in the stent 
group had an IOP of 21 mm Hg or lower without ocular 
hypotensive medications than in the control (phacoemul-
sification alone) group (P < .036). In addition, the IOP with 
one device was 17 mm Hg at year 1 and remained stable 
at 17.1 mm Hg at year 2. In the control group, the IOP 
drifted upward 0.8 mm Hg during year 1 to reach 17.8 mm 
Hg at year 2. These results indicate that the IOP reduction 
achieved with the iStent may be sustained. More patients 
were free of medication in the combined than the control 
group (61% vs 50%; P = .36.).1 This finding indicates that 
patients who wish to decrease their dependence on topical 
IOP-lowering medication after cataract surgery may want to 
consider an iStent. Of course, surgeons who were not a part 
of the device’s FDA studies are just now starting to evaluate 
the iStent and how it works in their hands versus in a clini-
cal trial. One of the problems that doctors have struggled 
with somewhat is the bidirectional movement required for 
positioning of the stent in Schlemm canal. First, the surgeon 
must use a medial-lateral movement to get the device 
across the anterior chamber, and then, an inferior motion is 
required to position the stent in the canal. A single motion 
across the anterior chamber in a direction toward the tra-
becular meshwork would be an easier option, because only 
medial-lateral movement would be required. 
Several years ago, Ike Ahmed, MD, reported on the IOP-
lowering effect from the placement of more than one iStent. 
He found that implanting two or three stents produced 
a lower mean IOP than the placement of a single stent.2 
Glaukos Corporation began a trial evaluating an injectable 
trabecular microbypass stent with two devices loaded in the 
same inserter (GTS 400 or the iStent Inject). This research is 
now a prospective, randomized, controlled, pivotal US inves-
tigational device exemption trial. The idea is to allow the 
surgeon to access two areas of the canal of Schlemm and to 
bypass the trabecular meshwork with two implants on the 
same inserter, using just a medial-lateral motion to get the 
devices into the meshwork. 
DESIGN
The iStent Inject is a single-piece, heparin-coated titanium 
stent with a length of 360 µm and a maximum width of  
230 µm. It has four outflow orifices that divert aqueous into 
approach (as used in canaloplasty) necessarily compro-
mises a portion of conjunctiva that may be needed for 
future surgery, whereas an ab interno approach pre-
serves the conjunctiva. The Hydrus Microstent appears 
to offer some of the same benefits as canaloplasty: 
dilation of Schlemm canal, improved outflow through 
the collector channels, and decreased resistance to flow 
across the trabecular meshwork. The additional advan-
tages of reduced surgical time, minimal postoperative 
complications, and efficient implantation hold great 
potential. 
Robert Marquis, MD, PhD, is a glaucoma specialist at 
Texan Eye Glaucoma Service in Austin, Texas. He is an 
investigator for Glaukos Corporation and Ivantis, Inc.  
Dr. Marquis may be reached at (512) 327-7000;  
rmarquis@swbell.net.
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Schlemm’s canal scaffold for IOP reduction after cataract surgery in open angle glaucoma. Poster presented at: 
American Glaucoma Society 22nd Annual Meeting; March 1, 2012; New York, NY.
2.  Samuelson TW, Pfeiffer N, Lorenz K. Six month results from a prospective, multicenter study of a nickel-titanium 
Schlemm’s canal scaffold for IOP reduction in open angle glaucoma. Poster presented at: American Glaucoma 
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Figure 1.  The flanged end penetrates the trabecular mesh-
work and stops with the thicker, flat end in the anterior 
chamber.
Figure 2.  Two stents positioned with 2 clock hours of separa-
tion between them lowered the IOP in this eye to 12 mm Hg 
on the first postoperative day from a preoperative washout 
level of 25 mm Hg. 
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the canal. The device can be implanted in the right or the 
left eye (unlike the iStent recently approved by the FDA that 
comes in right or left eye models). An outside area of reduced 
diameter, midway along the device, is designed to promote 
retention within the trabecular meshwork (Figure 1).
PROCEDURE
The sterile, single-use injector 
system is preloaded with two stents 
and designed to deliver them into 
Schlemm canal. The surgeon traverses 
the anterior chamber with the injec-
tor. Its tip has a sharpened, stainless 
steel trocar and a stainless steel inser-
tion tube with an insertion sleeve. The stents are aligned 
on the trocar and are within the insertion tube, which is 
contained within the insertion sleeve. The injector’s housing 
features an insertion sleeve retraction button and a stent 
release button. After the trocar penetrates the trabecular 
meshwork, the surgeon injects a stent by pushing the stent 
release trigger on the inserter system. After implantation, 
there are several clock hours of distance between the two 
stents (Figure 2). The idea behind using two stents is that 
they will get into the canal of Schlemm and, through closer 
proximity, tap more collector channels. This may decrease 
the IOP further than a single iStent. 
RESULTS
Two-year results for the first 121 patients who had a 
medicated IOP of 24 mm Hg or less before undergoing 
phacoemulsification combined with the implantation of 
the iStent Inject were released this year. At the time of 
analysis, 25 subjects who had received stents and 17 con-
trol subjects had completed 2 years of follow-up. Of those 
in the stent treatment group, 68% had an unmedicated 
IOP of 18 mm Hg or less versus 24% of the control group.3 
These results are encouraging, and the technology appears 
to represent an advance in the options for treating early to 
moderate open-angle glaucoma. 
E. Randy Craven, MD, is an associate clinical professor 
at Rocky Vista University in Parker, Colorado. Dr. Craven 
is a consultant to Ivantis Inc. and Transcend Medical and 
a stockholder in Solx, Inc. He has received research support 
from Glaukos Corporation, Ivantis Inc., and Transcend 
Medical. Dr. Craven may be reached at (303) 748-5102; 
ercraven@yahoo.com.
1.  Craven ER, Katz LJ, Wells JM, Giamporcaro JE. Cataract surgery with trabecular micro-bypass stent implantation 
in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 
2012;38:1339-1345. 
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3.  Bacharach J. Results from two years postoperative from prospective, randomized studies of second generation 
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By Michael S. Berlin, MD, MS; Marc Töteberg-
Harms, MD; Lea Kleineberg, MD; Richard P. 
Stodtmeister, MD; and Ulrich F. Giers, MD
The primary cause of elevated IOP in most cases of open-
angle glaucoma (OAG) is increased outflow resistance in 
the juxtacanalicular trabecular meshwork (TM) and inner 
wall of the canal of Schlemm.1 The goal of performing laser 
surgery at the anterior chamber angle is to re-establish a 
physiological aqueous outflow pathway. Experiments with 
photothermal and photodisruptive lasers (ruby, Nd:YAG, 
and argon) were compromised by scarring through inflam-
matory and healing responses.2-11 Excimer laser trabeculos-
tomy (in Europe, “trabeculotomy”; ELT) uses a nonthermal, 
short-pulsed, 308-nm, xenon-chloride excimer laser to ablate 
the TM. The pores created have sharp edges, thus avoiding 
scar formation.12-15
PROCEDURE
ELT can be performed as a standalone procedure or in 
combination with cataract surgery (phacoemulsification 
plus ELT). Local anesthesia is adequate. Visualization of the 
TM is achieved by gonioscopy or via an endoscope. A fiber 
optic probe enters the anterior chamber through a para-
centesis, and with the probe in direct contact with the TM, 
the pulsed laser energy is applied.16 In the current protocol, 
five to 10 pores are created over 90º of the TM (Figure). 
Slight retrograde bleeding from the canal of Schlemm is 
not considered a complication but indicates patency of the 
created pores. The decrease in IOP is usually present from 
the first day after the procedure and remains stable over 
time. The ELT procedure takes less than 5 minutes.17
RESULTS
The first human clinical trial of ELT was performed in 
Germany in 1997. In 22 eyes with OAG, the median reduc-
tion in IOP was 7 mm Hg.18 There was only minimal trauma 
to the eye. Of particular note, there is no conjunctival manip-
ulation to compromise later filtering surgery. 
Since 1997, numerous clinical studies have demonstrated 
ELT’s ability safely to achieve a long-term reduction in IOP. 
A retrospective study assessed 70 eyes after ELT and  
60 eyes after combined phacoemulsification plus ELT that 
had a diagnosis of primary OAG or ocular hypertension. 
ExcimEr LasEr TrabEcuLosTomy
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The study had a follow-up period of up to 26 months. The 
investigators reported a reduction of IOP in the ELT group 
from 24.1 ±0.7 mm Hg to 18.8 ±0.8 mm Hg after 1 year and 
to 16.8 ±1 mm Hg after 2 years (-30.3%), while the number 
of antiglaucoma drugs decreased slightly (1.9 ±0.1 dropping 
to 1.5 ±0.3 after 2 years). In the combined group, the IOP 
decreased from 22.4 ±0.6 mm Hg to 16.4 ±0.4 mm Hg at  
1 year and 12.8 ±1.5 mm Hg after 2 years (-42.9%), while the 
number of antiglaucoma drugs remained almost constant 
(from 1.1 ±0.2 to 1.2 ±0.2 after 2 years).17 
A recently published study exclusively analyzed combined 
phacoemulsification plus ELT (n = 24) and confirmed an 
immediate pressure-lowering effect. This study also con-
firmed a significant decrease in medication after a follow-up 
period of 1 year (25.5 ±2.9 mm Hg dropping to 16.5 ±5 mm 
Hg, -35.3%; antiglaucoma drugs, 2.3 ±1.3 dropping to 1.5 ±1.4, 
-34.8%).19
CONCLUSION
ELT is a promising, minimally invasive treatment for 
lowering IOP in eyes with OAG. It has been approved for 
use in the European Union and Switzerland for more than 
a decade. Currently, clinical studies and FDA approval are 
pending in the United States and Canada. 
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ExcimEr LasEr TrabEcuLosTomy (continued)
Figure.  Schematic and gonioscopic view (inset) of the 
anterior chamber angle with a 200-µm fiber-optic probe 
introduced through a paracentesis and in direct contact 
with the TM. The ablation zone of the laser from the TM 
to the canal of Schlemm is the shaded white area, which 
spares the outer wall of the canal. With a nonthermal  
308-nm XeCl excimer laser, the TM, juxtacanalicular TM, 
and inner wall of the canal of Schlemm are ablated to cre-
ate five to 10 pores.
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iStent Supra
By Jason Bacharach, MD
It is an exciting but challenging moment for 
physicians who treat patients with glaucoma. 
Surgeons desire less invasive techniques with 
quicker rehabilitation times, higher efficiency in 
the OR, and the ability to combine glaucoma procedures 
with cataract surgery. Microinvasive glaucoma surgery is 
characterized as a microincisional technique that involves 
no destruction of tissue, no corneal flaps, and no disrup-
tion of the conjunctiva. On the heels of the FDA’s approval 
of the iStent Trabecular Micro-Bypass Stent (model G-1), 
Glaukos Corporation has initiated clinical trials to develop 
a suprachoroidal device (the iStent Supra). The goal is to 
allow surgeons to lower IOP by enhancing uveoscleral or 
conventional outflow, both via an ab interno approach. 
 The iStent Supra is one of a few new technologies 
that attempt to harness a potentially vacuum-like effect 
of the suprachoroidal space by shunting aqueous to 
the area. Once in the suprachoroidal space, the aque-
ous exits either via a transscleral route or by choroidal 
absorption. Other technologies under investigation for 
use in the suprachoroidal space are the Solx Gold Shunt 
(Solx, Inc.) and the 
CyPass Micro-Stent 
(Transcend Medical). 
I have been a clini-
cal investigator of 
and have experience 
placing both the Solx 
Gold Shunt (via an 
ab externo approach) 
and the iStent Supra 
(via an ab interno 
approach). (For more on the Solx Gold Shunt, see the 
sidebar by Marlene R. Moster, MD, on this page.)
DESIGN
The iStent Supra is designed to create a patent lumen 
between the anterior chamber and the suprachoroidal 
space. It is made of poyethersulfone and has a colored 
titanium sleeve. The device also has a proprietary heparin 
coating (Duraflo) and is biocompatible. It is nonpyrogenic, 
nonferrous (not magnetic), and terminally sterilized (irradia-
tion). The stent is slightly curved to match the suprachoroi-
dal space. It features retention rings to provide stability at 
the site of implantation (Figure 1).
Figure 1.  The iStent Supra.
By Marlene R. Moster, MD
Successfully treating patients with 
refractory glaucoma remains an unmet 
surgical challenge. The Solx Gold Shunt 
(Solx, Inc.) has the potential to address 
this population without the forma-
tion of a bleb. This minimally invasive 
device is made of pure biocompatible 
gold and is placed in the suprachoroidal space via an elegant 
surgical procedure (Figure). The device is approved for use 
in Canada and Europe, and enrollment in its phase 3 US 
investigational device exemption trial is nearing completion. 
Although it is too early to report on the study’s results, the 
concept behind the device and previously reported data 
indicate that this shunt may represent an attractive future 
option for glaucoma specialists. 
Marlene R. Moster, MD, is a professor of 
ophthalmology at the Thomas Jefferson School 
of Medicine and is an attending surgeon at 
Wills Eye Institute, both in Philadelphia. She 
acknowledged no financial interest in the 
product or company mentioned herein. Dr. Moster may 
be reached at (215) 928-3342; marlenemoster@aol.com.
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Figure.  The Solx Gold Shunt.
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PROCEDURE
The iStent Supra can be implant-
ed in combination with cataract 
surgery or as a freestanding tech-
nique. The keys to successfully 
implanting the suprachoroidal 
device are clear visibility of the 
angle structures and a knowledge 
of the angle landmarks. The surgeon views the angle 
through a goniolens placed on the cornea. My tips for 
optimizing visibility are tilting the patient’s head away 
from the surgeon and zooming up the microscope’s 
power (10×-12×). The stent is implanted right below 
the scleral spur. Next, the trocar/stent is advanced into 
the suprachoroidal space until approximately 0.5 mm 
of the sleeve is left in the anterior chamber. Then, the 
surgeon engages a trigger mechanism on the inserter to 
release the stent (Figure 2).
RESULTS
Earlier this year, Eric Donnenfeld, MD, presented the 
results of a prospective, single-arm, open-label study of  
40 subjects (current enrollment, 37 eyes).1 The subjects 
had moderate to advanced glaucoma (cup-to-disc ratio 
≤ 0.9) and no history of surgical intervention for glau-
coma. Their preoperative IOP was 18 to 30 mm Hg on 
two medications (mean of currently enrolled subjects = 
20.7 ±2.5 mm Hg). Baseline IOP after washout was 22 to 
38 mm Hg (mean of currently enrolled subjects = 24.7 
±1.9 mm Hg). The treatment included one iStent Supra 
and one postoperative medication (travoprost). The 
study’s protocol includes 2 years of follow-up. 
Dr. Donnenfeld reported the status of 25 subjects 
through 1 year. The mean decrease in IOP at this time 
point was 43%, with a reduction of one medication. 
Ninety-six percent of patients met the primary efficacy 
endpoint of at least a 20% reduction in IOP. All eyes 
met the secondary endpoint of an IOP that was less 
than or equal to 18 mm Hg (the IOP was ≤ 15 mm Hg 
in 80% of subjects). There were no untoward adverse 
events intra- or postoperatively. Dr. Donnenfeld and 
his fellow investigators concluded that implanting the 
iStent Supra as a sole procedure is feasible, safe, and 
capable of significantly reducing IOP and the need for 
topical medical therapy in patients with open-angle 
glaucoma that was previously uncontrolled on two 
agents. The study is ongoing, and 2-year data are being 
collected.
CONCLUSION
The flipside to the excellent safety profile of microin-
vasive glaucoma surgery is that, in general, it lowers IOP 
less than more invasive procedures (ie, trabeculectomy 
and tube shunt surgery). An ab interno suprachoroidal 
shunt such as the iStent Supra may combine the best 
of these properties by achieving a lower IOP than ab 
interno stenting of Schlemm canal while maintaining 
conjunctival integrity.  n
Jason Bacharach, MD, is the director of research at 
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Figure 2.  The iStent Supra in the suprachoroidal space.
Direct link: https://www.research.net/s/GT8
Weigh in on  
this topic now!
In which of the following technologies not available 
in the United States are you currently the most 
interested? 
 AqueSys Implant 
 CyPass Micro-Stent  
 Excimer Laser Trabeculostomy 
 Hydrus Microstent  
 iStent Inject  
 iStent Supra  
 Solx Gold Shunt
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